{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:35:50Z","timestamp":1791588950297,"version":"4.3.4"},"reference-count":32,"publisher":"Institute of Biochemistry","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BIOMED KHIM"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:p>The interaction of inactivated poliovirus vaccine strains with oriented antibodies immobilized to protein A via Fc fragments has been investigated. Using an SPR biosensor, the kinetic and equilibrium parameters of the interaction of vaccine attenuated polioviruses of the Sabin strains type 1 and type 2, inactivated by various methods were determined. The strongest interaction was observed between polyclonal antibodies to Sabin strain type 2 poliovirus and Sabin strain type 2 poliovirus inactivated with \u03b2-propiolactone, KD = 1.04\u22c510-11 M, as well as the interaction of monoclonal antibodies to Sabin strain type 1 poliovirus and Sabin strain type 1 poliovirus inactivated with formaldehyde, KD = 1.39\u22c510-11 M. The high-affinity interaction of inactivated vaccine polioviruses of the Sabin strains type 1 and type 2 with immobilized antibodies indicates that the D-antigen retained its structure after virus inactivation with \u03b2-propiolactone or formaldehyde.<\/jats:p>","DOI":"10.18097\/pbmcr1507","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T08:37:37Z","timestamp":1741163857000},"page":"59-64","source":"Crossref","is-referenced-by-count":3,"title":["The SPR analysis of the interaction of inactivated poliovirus vaccine attenuated strains with antibodies"],"prefix":"10.18097","volume":"71","author":[{"given":"O.V.","family":"Gnedenko","sequence":"first","affiliation":[{"name":"Institute of Biomedical Chemistry, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu.Yu.","family":"Ivin","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Chemistry, Moscow, Russia; Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.N.","family":"Piniaeva","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Chemistry, Moscow, Russia; Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.N.","family":"Zyrina","sequence":"additional","affiliation":[{"name":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.V.","family":"Levin","sequence":"additional","affiliation":[{"name":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.S.","family":"Borisenko","sequence":"additional","affiliation":[{"name":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.D.","family":"Zhdanov","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Chemistry, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.S.","family":"Ivanov","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Chemistry, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.V.","family":"Lisitsa","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Chemistry, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.A.","family":"Ishmukhametov","sequence":"additional","affiliation":[{"name":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.I.","family":"Archakov","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Chemistry, Moscow, Russia; Pirogov Russian National Research Medical University, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7443","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Shuker S.B., Hajduk P.J., Meadows R.P., Fesik S.W. (1996) Discovering high-affinity ligands for proteins: SAR by NMR. Science, 274(5292), 1531\u20131534.","DOI":"10.1126\/science.274.5292.1531"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Mayer M., Meyer B. (1999) Characterization of ligand binding by saturation transfer difference NMR spectroscopy. Angewandte Chemie International Edition, 38(12), 1784\u20131788.","DOI":"10.1002\/(SICI)1521-3773(19990614)38:12<1784::AID-ANIE1784>3.3.CO;2-H"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Blundell T.L., Jhoti H., Abell C. (2002) High-throughput crystallography for lead discovery in drug design. Nat. Rev. Drug Discov., 1(1), 45\u201354.","DOI":"10.1038\/nrd706"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Duong-Thi M.-D., Bergstr\u00f6m M., Fex T., Isaksson R., Ohlson S. (2013) High-throughput fragment screening by affinity LC-MS. J. Biomol. Screen., 18(2), 160\u2013171.","DOI":"10.1177\/1087057112459271"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Ladbury J.E., Klebe G., Freire E. (2010) Adding calorimetric data to decision making in lead discovery: a hot tip. Nat. Rev. Drug Discov., 9(1), 23\u201327.","DOI":"10.1038\/nrd3054"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Lewis L.M., Engle L.J., Pierceall W.E., Hughes D.E., Shaw K.J. (2004) Affinity capillary electrophoresis for the screening of novel antimicrobial targets. J. Biomol. Screen., 9(4), 303\u2013308.","DOI":"10.1177\/1087057104263439"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Duong-Thi M.-D., Meiby E., Bergstr\u00f6m M., Fex T., Isaksson R., Ohlson S. (2011) Weak affinity chromatography as a new approach for fragment screening in drug discovery. Anal. Biochem., 414(1), 138\u2013146.","DOI":"10.1016\/j.ab.2011.02.022"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Wang X., Li M., Lin Z., Pan H., Tang Z., Zheng Z., Li S., Zhang J., Xia N., Zhao Q. (2018) Multifaceted characterization of recombinant protein-based vaccines: an immunochemical toolbox for epitope-specific analyses of the hepatitis E vaccine. Vaccine, 36(50), 7650\u20137658.","DOI":"10.1016\/j.vaccine.2018.10.089"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Yin X., Wang X., Zhang Z., Li Y., Lin Z., Pan H., Gu Y., Li S., Zhang J., Xia N., Zhao Q. (2020) Demonstration of real-time and accelerated stability of hepatitis E vaccine with a combination of different physicochemical and immunochemical methods. J. Pharm. Biomed. Anal., 177, 112880.","DOI":"10.1016\/j.jpba.2019.112880"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Narayan K., Paduraru C., Blake T., Arunachalam A.B. (2023) Rapid determination of influenza vaccine potency by an SPR-based method using subtype or lineage-specific monoclonal antibodies. Front. Immunol., 14, 1128683.","DOI":"10.3389\/fimmu.2023.1128683"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Wen Y., Trinh H.V., Linton C.E., Tani C., Norais N., Martinez-Guzman D., Ramesh P., Sun Y., Situ F., Karaca-Griffin S., Hamlin C., Onkar S., Tian S., Hilt S., Malyala P., Lodaya R., Li N., Otten G., Palladino G., Friedrich K., Aggarwal Y., LaBranche C., Duffy R., Shen X., Tomaras G.D., Montefiori D.C., Fulp W., Gottardo R., Burke B., Ulmer J.B., Zolla-Pazner S., Liao H.X., Haynes B.F., Michael N.L., Kim J.H., Rao M., O'Connell R.J., Carfi A., Barnett S.W. (2018) Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant. PLOS One, 13(4), e0194266.","DOI":"10.1371\/journal.pone.0194266"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Deschuyteneer M., Elouahabi A., Plainchamp D., Plisnier M., Soete D., Corazza Y., Lockman L., Giannini S., Deschamps M. (2010) Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix\u2122, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine. Human Vaccines, 6(5), 407\u2013419.","DOI":"10.4161\/hv.6.5.11023"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Piniaeva A.N., Kovpak A.A., Ivin Y.Y., Shishova A.A., Sorokin A.A., Prostova M.A., Belyakova A.V., Siniugina A.A., Ishmukhametov A.A., Hapchaev Y.H., Gmyl A.P. (2021) Selection of sorbent for poliovirus vaccine strain concentrate purification by gel filtration. Biotekhnologiya, 37(6), 84\u201394.","DOI":"10.21519\/0234-2758-2021-37-6-84-94"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Piniaeva A., Ignatyev G., Kozlovskaya L., Ivin Y., Kovpak A., Ivanov A., Shishova A., Antonova L., Khapchaev Y., Feldblium I., Ivanova O., Siniugina A., Ishmukhametov A. (2021) Immunogenicity and safety of inactivated Sabin-strain polio vaccine \u201cPoliovacSin\u201d: clinical trials phase I and II. Vaccines, 9(6), 565.","DOI":"10.3390\/vaccines9060565"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Wilton T., Dunn G., Eastwood D., Minor P.D., Martin J. (2014) Effect of formaldehyde inactivation on poliovirus. J. Virol., 88(20), 11955\u201311964.","DOI":"10.1128\/JVI.01809-14"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Jiang S.D., Pye D., Cox J.C. (1986) Inactivation of poliovirus with \u03b2-propiolactone. J. Biol. Stand., 14(2), 103\u2013109.","DOI":"10.1016\/0092-1157(86)90028-4"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Elveborg S., Monteil V.M., Mirazimi A. (2022) Methods of inactivation of highly pathogenic viruses for molecular, serology or vaccine development purposes. Pathogens, 11(2), 271.","DOI":"10.3390\/pathogens11020271"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Zhdanov D.D., Ivin Yu.Yu., Shishparenok A.N., Kraevskiy S.V., Kanashenko S.L., Agafonova L.E., Shumyantseva V.V., Gnedenko O.V., Pinyaeva A.N., Kovpak A.A., Ishmukhametov A.A., Archakov A.I. (2023) Perspectives for the creation of a new type of vaccine preparations based on pseudovirus particles using polio vaccine as an example. Biomeditsinskaya Khimiya, 69(5), 253\u2013280.","DOI":"10.18097\/PBMC20236905253"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Wood D.J., Heath A.B., Sawyer L.A. (1995) A WHO collaborative study on assays of the antigenic content of inactivated poliovirus vaccines. Biologicals, 23(1), 83\u201394.","DOI":"10.1016\/1045-1056(95)90017-9"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Wood D.J., Heath A.B. (1995) A WHO collaborative study of immunogenicity assays of inactivated poliovirus vaccines. Biologicals, 23(4), 301\u2013311.","DOI":"10.1006\/biol.1995.0049"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Kersten G., Hazendonk T., Beuvery C. (1999) Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains. Vaccine, 17(15\u201316), 2059\u20132066.","DOI":"10.1016\/s0264-410x(98)00409-5"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Westdijk J., Brugmans D., Martin J., van't Oever A., Bakker W.A.M., Levels L., Kersten G. (2011) Characterization and standardization of Sabin based inactivated polio vaccine: proposal for a new antigen unit for inactivated polio vaccines. Vaccine, 29(18), 3390\u20133397.","DOI":"10.1016\/j.vaccine.2011.02.085"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Westdijk J., van der Maas L., Ten Have R., Kersten G. (2016) Measuring poliovirus antigenicity by surface plasmon resonance. Application for potency indicating assays. Methods Mol. Biol., 1387, 299\u2013323.","DOI":"10.1007\/978-1-4939-3292-4_16"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Agafonova L.E., Shumyantseva V.V., Ivin Yu.Yu., Piniaeva A.N., Kovpak A.A., Ishmukhametov A.A., Budnik S.V., Churyukin R.S., Zhdanov D.D., Archakov A.I. (2024) Electrochemical profiling of poliovirus particles inactivated by chemical method and ionizing radiation. Biomeditsinskaya Khimiya, 70(3), 161\u2013167.","DOI":"10.18097\/PBMC20247003161"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Kovpak A.A., Ivin Y.Y., Piniaeva A.N., Khapchaev Y.K. Ozherelkov S.V., Belyakova A.V., Ishmukhametov A.A. (2021) Application of ultrafiltration membranes for purification and concentration of Sabin poliovirus type 1. Journal of Microbiology, Epidemiology and Immunobiology, 98(2), 135\u2013143.","DOI":"10.36233\/0372-9311-94"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Piniaeva A.N., Kovpak A.A., Ivin Y.Y., Sandzhieva S.H., Shishova A.A., T\u0441elykh I.O., Vasilenko V.E., Kaa K.V., Mazhed Zh.H., Khapchaev Yu.Kh., Siniugina A.A., Ishmukhametov A.A. (2022) Application of ion exchange chromatography in the development of technology to obtain inactivated poliovirus vaccine. Epidemiology and Vaccinal Prevention, 21(5), 107\u2013119.","DOI":"10.31631\/2073-3046-2022-21-5-107-119"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Yablokov E., Sushko T., Ershov P., Florinskaya A., Gnedenko O., Shkel T., Grabovec I., Strushkevich N., Kaluzhskiy L., Usanov S., Gilep A., Ivanov A. (2019) A large-scale comparative analysis of affinity, thermodynamics and functional characteristics of twelve cytochrome P450 isoforms and their redox partners. Biochimie, 162, 156\u2013166.","DOI":"10.1016\/j.biochi.2019.04.020"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Barykin E.P., Garifulina A.I., Tolstova A.P., Anashkina A.A., Adzhubei A.A., Mezentsev Y.V., Shelukhina I.V., Kozin S.A., Tsetlin V.I., Makarov A.A. (2020) Tetrapeptide Ac-HAEE-NH2 protects \u03b14\u03b22 nAChR from inhibition by A\u03b2. Int. J. Mol. Sci., 21(17), 6272.","DOI":"10.3390\/ijms21176272"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Ivanov A.S., Gnedenko O.V., Molnar A.A., Archakov A.I., Podust L.M. (2010) FMN binding site of yeast NADPH-cytochrome P450 reductase exposed at the surface is highly specific. ACS Chem. Biol., 5(8), 767\u2013776.","DOI":"10.1021\/cb100055v"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Rakhmetova S.Yu., Radko S.P., Gnedenko O.V., Bodoev N.V., Ivanov A.S., Archakov A.I. (2010) Comparative termodynamic analysis of thrombin interaction with anti-thrombin aptamers and their heterodimeric construct. Biomeditsinskaya Khimiya, 56(3), 404\u2013411.","DOI":"10.18097\/PBMC20105603404"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Dubs M.C., Altschuh D., van Regenmortel M.H. (1992) Interaction between viruses and monoclonal antibodies studied by surface plasmon resonance. Immunol. Lett., 31(1), 59\u201364.","DOI":"10.1016\/0165-2478(92)90011-c"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Bright R.A., Carter D.M., Crevar C.J., Toapanta F.R., Steckbeck J.D., Cole K.S., Kumar N.M., Pushko P., Smith G., Tumpey T.M., Ross T.M. (2008) Cross-clade protective immune responses to influenza viruses with H5N1 HAand NAelicited by an influenza virus-like particle. PLOS One, 3(1), e1501.","DOI":"10.1371\/journal.pone.0001501"}],"container-title":["Biomeditsinskaya Khimiya"],"original-title":[],"language":"ru","deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T08:38:06Z","timestamp":1741163886000},"score":1,"resource":{"primary":{"URL":"http:\/\/pbmc.ibmc.msk.ru\/en\/article-en\/PBMC-2025-71-1-59"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025]]},"published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.18097\/pbmcr1507","relation":{},"ISSN":["2310-6905","2310-6972"],"issn-type":[{"value":"2310-6905","type":"electronic"},{"value":"2310-6972","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}